On November 7, Korea Pharma announced that it will collaborate with Emotive, a company specializing in digital therapeutics, to launch a non-pharmaceutical digital therapeutic device for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children.
The digital therapeutic device to be introduced by the two companies is a game-based cognitive training solution designed based on cognitive modeling. It is intended to help improve children's attention span and concentration.
This device has already secured clinical evidence, and its application is expected to expand in medical settings both in Korea and abroad. At the Autumn Academic Conference of the Korean Academy of Child and Adolescent Psychiatry held on the same day, the two companies will showcase the product at a joint booth, marking the start of their marketing activities.
Korea Pharma is expanding its business beyond its existing portfolio focused on central nervous system (CNS) pharmaceuticals to the digital-based, non-pharmaceutical treatment sector. The company plans to build an integrated CNS treatment ecosystem that combines pharmaceuticals and digital therapeutic devices.
A representative from Korea Pharma stated, "Mental health for children and adolescents is a crucial area directly linked to the sustainability of society," adding, "By entering the digital therapeutic device market, we aim to expand the current pharmaceutical-centered treatment paradigm and provide more efficient and personalized treatment solutions."
Meanwhile, Korea Pharma is in the process of obtaining approval from the Ministry of Food and Drug Safety for 'Metidue Extended-Release Capsule' (active ingredient: methylphenidate hydrochloride), a 24-hour sustained-release ADHD medication. The company aims to strengthen its position as a CNS specialist by combining this digital therapeutic collaboration with a convergence of pharmaceutical and non-pharmaceutical approaches.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
